08:00 , Jan 21, 2016 |  BC Innovations  |  Finance

Italy's velocity factor

After five years of building a portfolio of research programs, Italian tech transfer company TTFactor s.r.l. can now turn to a homegrown supply of seed funding following the launch of BiovelocITA, the country's first biotech...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Cancer Research UK, Monopar Therapeutics deal

Cancer Research UK will fund and complete preclinical development of Monopar’s HuATN-658 and conduct a Phase I trial of the product in cancer patients. Upon completion of the Phase I trial, Monopar will have the...
08:00 , Mar 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR) Mouse studies suggest anti-uPAR antibodies could help treat aggressive breast cancer. In...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Tactic Pharma, Wilson Therapeutics deal

Wilson acquired Decuprate ( ATN-224 ) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an inability...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease End-stage renal disease (ESRD) Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR) A study in mice and in patient samples suggests...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Plasminogen activator, urokinase receptor (PLAUR; UPAR) In vitro and mouse studies suggest that plasmin could help improve stem cell...
07:00 , Aug 14, 2008 |  BC Innovations  |  Targets & Mechanisms

Blocking Blood Vessel Buildup

A study by Japanese and Austrian researchers published in The Journal of Clinical Investigation has uncovered a connection between the angiotensin II type 1 receptor and the lipoprotein receptor sortilin-related receptor, L(DLR class) A repeats-containing...
08:00 , Nov 6, 2002 |  BC Extra  |  Company News

Angstrom names Thompson as CEO

Angstrom Pharmaceuticals (San Diego, Calif.) hired Virgil Thompson as president and CEO. Thompson previously was the president of Bio-Technology General (BTGC). Angstrom is developing inhibitors of the urokinase Plasminogen Activator System ( uPA /uPAR) to...
07:00 , Jul 22, 2002 |  BC Week In Review  |  Company News

University of California other research news

Researchers published in the Proceedings of the National Academy of Sciences evidence for the use of UPAR as an endometrial cancer diagnostic. Analysis of 65 tumor samples showed UPAR protein expression highly correlated with stage...